![Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression - ScienceDirect Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0049017220302201-gr1.jpg)
Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression - ScienceDirect
![Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency - Journal of Allergy and Clinical Immunology Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency - Journal of Allergy and Clinical Immunology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4ff523df-8e05-4e4e-a6e6-6ab0db242181/gr1_lrg.jpg)
Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency - Journal of Allergy and Clinical Immunology
![Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients - Multiple Sclerosis and Related Disorders Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients - Multiple Sclerosis and Related Disorders](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/07c04668-8914-4fb2-8503-90e11d1ea907/gr1_lrg.jpg)
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients - Multiple Sclerosis and Related Disorders
![Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE | Pediatric Rheumatology | Full Text Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE | Pediatric Rheumatology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12969-021-00627-w/MediaObjects/12969_2021_627_Fig5_HTML.png)
Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE | Pediatric Rheumatology | Full Text
![JCM | Free Full-Text | A Follow-Up Study of a European IgG4-Related Disease Cohort Treated with Rituximab | HTML JCM | Free Full-Text | A Follow-Up Study of a European IgG4-Related Disease Cohort Treated with Rituximab | HTML](https://www.mdpi.com/jcm/jcm-10-01329/article_deploy/html/images/jcm-10-01329-g001.png)
JCM | Free Full-Text | A Follow-Up Study of a European IgG4-Related Disease Cohort Treated with Rituximab | HTML
![AB0213 SAVING GLUCOCORTICOIDS AFTER RITUXIMAB TREATMENT IN PATIENTS WITH REUMATOID ARTHRITIS. ANALYSIS OF A COMMON CLINICAL PRACTICE COHORT | Annals of the Rheumatic Diseases AB0213 SAVING GLUCOCORTICOIDS AFTER RITUXIMAB TREATMENT IN PATIENTS WITH REUMATOID ARTHRITIS. ANALYSIS OF A COMMON CLINICAL PRACTICE COHORT | Annals of the Rheumatic Diseases](https://ard.bmj.com/content/annrheumdis/80/Suppl_1/1132.3/F1.large.jpg)
AB0213 SAVING GLUCOCORTICOIDS AFTER RITUXIMAB TREATMENT IN PATIENTS WITH REUMATOID ARTHRITIS. ANALYSIS OF A COMMON CLINICAL PRACTICE COHORT | Annals of the Rheumatic Diseases
![A prospective cohort study of rituximab in the treatment of refractory nephrotic syndrome | SpringerLink A prospective cohort study of rituximab in the treatment of refractory nephrotic syndrome | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11255-021-02860-4/MediaObjects/11255_2021_2860_Fig1_HTML.png)
A prospective cohort study of rituximab in the treatment of refractory nephrotic syndrome | SpringerLink
![Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis - ScienceDirect Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0165572819300645-ga1.jpg)
Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis - ScienceDirect
![MYC predetermines the sensitivity of gastrointestinal cancer to antifolate drugs through regulating TYMS transcription - eBioMedicine MYC predetermines the sensitivity of gastrointestinal cancer to antifolate drugs through regulating TYMS transcription - eBioMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/54d3f666-b588-436f-a7e4-79c1145c3415/gr1.jpg)
MYC predetermines the sensitivity of gastrointestinal cancer to antifolate drugs through regulating TYMS transcription - eBioMedicine
The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study | Haematologica
![Frontiers | Lactobacillus reuteri Alleviates Gastrointestinal Toxicity of Rituximab by Regulating the Proinflammatory T Cells in vivo | Microbiology Frontiers | Lactobacillus reuteri Alleviates Gastrointestinal Toxicity of Rituximab by Regulating the Proinflammatory T Cells in vivo | Microbiology](https://www.frontiersin.org/files/Articles/645500/fmicb-12-645500-HTML/image_m/fmicb-12-645500-g001.jpg)
Frontiers | Lactobacillus reuteri Alleviates Gastrointestinal Toxicity of Rituximab by Regulating the Proinflammatory T Cells in vivo | Microbiology
![Preliminary results from a phase 1b double-blind study to assess the safety, tolerability and efficacy of intra-articular administration of resiniferatoxin or placebo for the treatment of moderate to severe pain due to Preliminary results from a phase 1b double-blind study to assess the safety, tolerability and efficacy of intra-articular administration of resiniferatoxin or placebo for the treatment of moderate to severe pain due to](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/d23cf50e-d34f-4724-9243-071435a1ccd6/fx1.jpg)